Please send you resume to CareerDevelopment@rvacmed.com

Responsibilities:

1. Act as a subject-matter expert for nucleic acid delivery technologies and provide key input on discovery and early development programs

2. Apply knowledge of nucleic acid delivery to prepare and characterize RNA and delivery vehicle including lipid nanoparticles.

3. Characterization and analysis of biophysical nanoparticle attributes

4. Provide formulations that support the final form and stability of RNA vaccines and therapeutics

5. Application of QbD principles and assessment of program/project risks that relate to delivery vehicle, formulations, process scale-up/scale-down, and work with GMP, Regulatory, and Quality to manage riskes  

6. Execute Informal stability studies on RNA-LNP product candidates

7. Think creatively to understand, trouble-shoot, and solve complex challenges, note program risks, and evaluate new technologies to ensure brilliant execution of function and program objectives. 

Qualifications:

1. Working knowledge of non-viral nucleic acid delivery and key delivery vehicle platforms that include lipid nanoparticles, polymers, dendrimers, etc.

2. English fluency (written and spoken)

3. Strong capability with business software (Office 365 including, Teams, Outlook, Powerpoint, and excel)

4. Strong written and oral presentation abilities.  

5. Functional Understanding of Quality by Design (QbD) principles

6. Prior experience executing technical risk assessments (TRA) and tech transfer of a discovery/early development program to a GMP manufacturer (internal or external)

7. Track record of strong research contributions that could be demonstrated with first-authored publications in peer-reviewed scientific journals    

8. Education: PhD with 1-2 years of experience (Preferred), MS with 3+ years of experience, BS with 5 or more years of experience

9. 1-2 (minimum) or  2-5 years of experience (preferred) at an industrial research company or organization

10. Experience with non-viral delivery systems for nucleic acids.

Preferred preparation of lipid nanoparticles and RNA or other nucleic acids